This content is only available within our institutional offering.
14 Sep 2018
LIBERUM: Roche - R&D call provides much greater clarity on biosimilars and highlights pipeline optionality
Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
LIBERUM: Roche - R&D call provides much greater clarity on biosimilars and highlights pipeline optionality
Roche Holding Ltd Dividend Right Cert. (RHO5:ETR) | 0 0 1.1% | Mkt Cap: 194,207m
- Published:
14 Sep 2018 -
Author:
Graham Doyle -
Pages:
4